C1S and hereditary angioedema: Therapeutic success and safety for PK inhibition has already been demonstrated in the disease of hereditary angioedema (HAE), which harbors deficiency or dysfunction in the C1-esterase inhibitor that normally inhibits PK and activates FXII [42].